Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of September 2022. The Company is a foreign private issuer based in Tel Aviv, Israel, with a wholly-owned U.S. subsidiary, RedHill Biopharma Inc. The filing primarily addresses a significant legal and financial dispute regarding the Company's credit facilities.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or total debt. However, it highlights the following financial status indicators:
- Debt Status: The Company has outstanding obligations under a Credit Agreement dated February 23, 2020.
- Interest Rate: Due to alleged defaults, outstanding obligations now bear interest at the default rate prescribed in the Credit Agreement.
- Liquidity and Reporting: The Company acknowledged a failure to deliver condensed consolidated interim financial statements for the quarter ended June 30, 2022, within the required 60-day window, though it anticipated public release by September 23, 2022.
Material Changes and Events
The most significant development reported is the receipt of a Notice of Events of Default and Reservation of Rights on September 13, 2022, from HCR Collateral Management, LLC (the administrative agent). Key details include:
- Alleged Defaults: The Notice asserts breaches of representations, warranties, and financial covenants under the Credit Agreement.
- Consequences: The Notice states that lenders may accelerate the obligations under the Credit Agreement.
- Reporting Delay: The Company admitted to missing the deadline for delivering Q2 2022 financial statements to the lender, a fact not explicitly asserted as a default in the Notice but acknowledged by management.
Management Commentary, Risks, and Outlook
Management disputes the validity of the Notice and the alleged events of default, having sent a formal response letter on September 15, 2022. The Company is engaged in good faith negotiations with HCR to reach a consensual business resolution. Strategic actions include:
- Operations: RedHill US continues to operate as usual.
- Strategic Alternatives: The Company is evaluating options to satisfy outstanding obligations, including a potential strategic transaction regarding its product Movantik®.
- Advisors: The Company has engaged Cravath, Swaine & Moore LLP as legal counsel and financial advisors to assist in these efforts.
- Risks: The primary risk is the acceleration of debt obligations and the potential inability to resolve the dispute with lenders, which could impact liquidity and operations.
Investor Verification Checklist
- Verify the outcome of the dispute with HCR Collateral Management, LLC regarding the alleged defaults.
- Confirm the release and contents of the condensed consolidated interim financial statements for the quarter ended June 30, 2022.
- Monitor progress on the potential strategic transaction involving Movantik®.
- Assess the impact of the default interest rate on the Company's cash flow and debt service requirements.
- Review any subsequent filings regarding the acceleration of debt obligations or restructuring efforts.